V3-positive cases comprise approximately one-third of all ALK+ NSCLC and present with more aggressive disease already at baseline, as evident by a higher number of metastatic sites at initial diagnosis [22,23,24,99]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.